Composition:

Each Serpass 50 mg film-coated tablet contains Sertraline hydrochloride 55.96 mg equivalent to sertraline 50 mg.

Each Serpass 100 mg film-coated tablet contains Sertraline hydrochloride 111.92 mg equivalent to sertraline 100 mg.

Therapeutic Indications:

Serpass is indicated for the treatment of:

Major depressive episodes. Prevention of recurrence of major depressive episodes.

Panic disorder, with or without agoraphobia.

Obsessive compulsive disorder (OCD) in adults and pediatric patients aged 6-17 years.

Social anxiety disorder.

Post-traumatic stress disorder (PTSD).

Approved by Egyptian Drug Authority: HF0294OA4548/102025 . Invalidation date: 20/10/2026

Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at www.edaegypt.gov.eg”